BiomX Inc. (NYSEAMERICAN:PHGE) to Post FY2023 Earnings of ($0.56) Per Share, HC Wainwright Forecasts

BiomX Inc. (NYSEAMERICAN:PHGEFree Report) – Analysts at HC Wainwright dropped their FY2023 EPS estimates for shares of BiomX in a report released on Tuesday, November 14th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.56) per share for the year, down from their prior estimate of ($0.52). HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for BiomX’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for BiomX’s Q4 2023 earnings at ($0.13) EPS, FY2024 earnings at ($0.50) EPS, FY2025 earnings at ($0.43) EPS and FY2026 earnings at ($0.48) EPS.

BiomX Trading Up 8.4 %

NYSEAMERICAN PHGE opened at $0.41 on Thursday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. BiomX has a 12 month low of $0.13 and a 12 month high of $0.69. The company has a market capitalization of $18.90 million, a P/E ratio of -0.54 and a beta of 1.34.

BiomX (NYSEAMERICAN:PHGEGet Free Report) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03).

About BiomX

(Get Free Report)

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).

See Also

Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with's FREE daily email newsletter.